Gastrointestinal symptoms of coronavirus disease 2019 (COVID-19), including diarrhea, nausea, and vomiting, are more common than previously thought. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) likely causes these symptoms by infecting the epithelial cells lining the gastrointestinal tract,[@bib1] with ACE2 functioning as the viral receptor[@bib2] and TMPRSS2 functioning in viral spike protein priming.[@bib3] Du et al[@bib4] recently reported that ACE2 not only is co-expressed in lung AT2 cells but also highly expressed in absorptive enterocytes. However, the regulatory mechanisms and transcription factors driving expression of *Ace2* and *Tmprss2* remains unclear. Using epigenomic approaches and mouse genetic models, we identify 4 key transcriptional regulators (CDX2, HNF4 factors, SMAD4, or GATA factors) that bind to the loci of these genes, alter chromatin looping, shape epigenetic modifications, and, ultimately, show a dramatic impact on *Ace2* and *Tmprss2* gene expression upon transcription factor knockout.

We began by investigating the expression of COVID-19--related host genes throughout the body. Chromatin accessibility and RNA transcript levels show a tissue-specific expression pattern for *Ace2* and *Tmprss2*, with greatest expression observed in intestine, kidney, and lung tissues ([Figure 1](#fig1){ref-type="fig"} *A* and *B* and [Supplementary Figure 1](#appsec1){ref-type="sec"}). *Ace2* and *Tmprss2* are expressed more robustly in isolated intestinal epithelium compared with the remaining subepithelium ([Figure 1](#fig1){ref-type="fig"} *C*). Temporally, transcript levels of *Ace2* and *Tmprss2* increase during embryonic development ([Figure 1](#fig1){ref-type="fig"} *D* and *F*). In the adult tissue, *Ace2* transcripts are increased in the villus compared with the crypt ([Figure 1](#fig1){ref-type="fig"} *E* and *F*). We next focused on the epithelial cell populations expressing the SARS-CoV-2--related genes. scRNA sequencing analysis defined cell populations within crypt epithelium that express markers of stem, progenitor, and differentiating epithelial cells ([Supplementary Figure 2](#appsec1){ref-type="sec"} *A*). Cells expressing canonic goblet, Paneth, tuft, enteroendocrine, or enterocyte lineage markers were each identified, as expected ([Supplementary Figure 2](#appsec1){ref-type="sec"} *B--F*, respectively). Other transcripts are expressed more broadly throughout the epithelium ([Supplementary Figure 2](#appsec1){ref-type="sec"} *G*). We found *Ace2* expression to be enriched in cells co-expressing mature enterocyte markers, whereas *Tmprss2* was expressed more broadly throughout the epithelium ([Supplementary Figure 2](#appsec1){ref-type="sec"} *H*).Figure 1***Ace2* and *Tmprss2* are highly expressed in the intestinal epithelium.** (*A*) DNase sequencing (DNase-seq) (GSE51336) enrichment at gene loci of *Ace2* and *Tmprss2* among different tissues. (*B*) RNA sequencing (RNA-seq) (GSE36025) tracks of *Ace2* and *Tmprss2* in different tissues. (*C*) Microarray data of mesenchymal and epithelial cells of the developing intestine (GSE6383). Data are collected from microarray probes showing representative expression fold change. (*D*) RNA sequencing of intestinal epithelium (GSE115541) shows that *Ace2* and *Tmprss2* increasingly are expressed across developmental time, from embryonic day (E)12.5 to adult. (*E*) In the adult tissue, *Ace2* is expressed more robustly in the villus vs the crypt cells (GSE53545, GSE70766, and GSE102171). Data are presented as means ± SEM. ∗∗∗*P* \< .001. (*F*) IGV tracks of RNA sequencing. ADVil, \_\_\_\_\_; FPKM, \_\_\_\_\_.

We next examined how intestinal transcription factor regulatory networks impact the expression of genes important for SARS-CoV-2 infection. CDX2 is required for specification of the intestine during embryonic development,[@bib5] and in adult life is required for intestinal maturation and proper enterocyte function.[@bib6] HNF4 factors are required for maturation of the embryonic intestine,[@bib7] and work in conjunction with SMAD4 to promote expression of adult enterocyte genes.[@bib8] GATA family transcription factors are important for intestinal regionalization.[@bib9] Chromatin immunoprecipitation sequencing of these transcription factors shows multiple binding regions at the loci of genes involved in CoV-2 infection ([Figure 2](#fig2){ref-type="fig"} *A*). Notably, the binding regions occur at locations of accessible chromatin (indicated by ATAC-seq in pink in [Figure 2](#fig2){ref-type="fig"} *A*), consistent with transcriptional enhancer functions. Active chromatin modifications were observed at these loci, and, importantly, chromatin modifications at the *Ace2* locus showed dependence on knockout of CDX or HNF factors in the epithelium using the *Villin-Cre* ^*ERT2*^ driver (indicated by asterisks in [Figure 2](#fig2){ref-type="fig"} *B*). Aside from *Ace2*, we also observed increased levels of these active chromatin modifications at the *Tmprss2* locus upon knockout of HNF4 or CDX transcription factors ([Figure 2](#fig2){ref-type="fig"} *B*). Altered chromatin structure at the *Ace2* and *Tmprss2* loci upon CDX and HNF4 loss would predict a corresponding change in transcript levels in these knockout models. Indeed, *Ace2* was down-regulated significantly upon loss of CDX2, HNF4 factors, SMAD4, or GATA factors ([Figure 2](#fig2){ref-type="fig"} *C--F*). Although *Ace2* levels were diminished in these knockout models, *Tmprss2* showed an increase in transcript levels ([Figure 2](#fig2){ref-type="fig"} *C--F*). Finally, consistent with their dynamic expression changes in response to HNF4 knockout, we also observed dynamic chromatin looping events at these loci, as measured by HiChIP.[@bib10] Although the *Ace2* locus showed fewer chromatin looping events upon HNF4 knockout, the *Tmprss2* locus showed increased contacts between presumed enhancers and the *Tmprss2* transcriptional start site ([Figure 2](#fig2){ref-type="fig"} *G*).Figure 2**HNF4, CDX2, SMAD4, and GATA transcription factors are key regulators of *Ace2* and *Tmprss2* expression in the intestinal epithelium.** (*A*) Chromatin accessibility (ATAC-seq) and transcription factor binding (chromatin immunoprecipitation sequencing \[ChIP-seq\]) at COVID-19--related gene loci. (*B*) Histone post-translational modifications associated with enhancers and promoters are reduced upon knockout of either CDX or HNF4 at the *Ace2* locus (indicated by asterisks), and, conversely, are unchanged or increase at the *Tmprss2* locus. (*C--F*) Transcriptome analysis to measure corresponding gene expression changes of COVID-19--related host genes upon knockout of these transcription factors (∗*P* \< .05, ∗∗*P* \< .01, and ∗∗∗*P* \< .001). (*G*) H3K4me3-HiChIP assays to measure 3-dimensional enhancer--promoter looping show multiple contacts between COVID-related gene promoters and nearby regulatory elements. Loops are visualized by Sushi, and shown with q ≤ 0.0001 and counts ≥ 8 (2 combined biological replicates per condition). FPKM, \_\_\_\_\_; MNase, \_\_\_\_\_; WT, wild-type.

This study provides an overview of how the genes known to facilitate SARS-CoV-2 infection are spatially and temporally expressed and transcriptionally regulated. Transcription factors function in complex and collaborative networks to promote proper cell function. It is interesting that 4 key intestinal transcription factors, CDX2, HNF4 factors, SMAD4, or GATA factors, all activate *Ace2* in the intestine. In addition, these transcription factors also might work as suppressors for *Tmprss2*, because *Tmprss2* is increased upon loss of these key intestinal transcription factors. These findings could help understand variable susceptibility to COVID-19 within the population owing to variable utilization of these transcription factors or their binding sites, which might cause variable expression of *Ace2* or *Tmprss2*. These regulatory mechanisms ultimately could lead to potential avenues for altering host gene expression to reduce the susceptibility or severity of SARS-CoV-2 infection.
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